These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34723071)

  • 21. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy.
    Ke Q; Zhao ZY; Mendell JR; Baker M; Wiley V; Kwon JM; Alfano LN; Connolly AM; Jay C; Polari H; Ciafaloni E; Qi M; Griggs RC; Gatheridge MA
    World J Pediatr; 2019 Jun; 15(3):219-225. PubMed ID: 30904991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials.
    Gissy JJ; Johnson T; Fox DJ; Kumar A; Ciafaloni E; van Essen AJ; Peay HL; Martin A; Lucas A; Finkel RS;
    Neuromuscul Disord; 2017 Oct; 27(10):905-910. PubMed ID: 28739181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gait deviations in Duchenne muscular dystrophy-Part 1. A systematic review.
    Goudriaan M; Van den Hauwe M; Dekeerle J; Verhelst L; Molenaers G; Goemans N; Desloovere K
    Gait Posture; 2018 May; 62():247-261. PubMed ID: 29579701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is It Possible to Have Home E-Monitoring of Pulmonary Function in Our Patients with Duchenne Muscular Dystrophy in the COVID-19 Pandemic?-A One Center Pilot Study.
    Wasilewska E; Sobierajska-Rek A; Małgorzewicz S; Soliński M; Szalewska D; Jassem E
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upper Extremity Examination for Neuromuscular Diseases (U-EXTEND): Protocol for a Multimodal Feasibility Study.
    Gutierrez R; McCrady A; Masterson C; Tolman S; Boukhechba M; Barnes L; Blemker S; Scharf R
    JMIR Res Protoc; 2022 Oct; 11(10):e40856. PubMed ID: 36301603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seeking a better landscape for therapy development in neuromuscular disorders.
    Larkindale J; Porter JD
    Muscle Nerve; 2018 Jan; 57(1):16-19. PubMed ID: 28881009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy.
    Ricotti V; Kadirvelu B; Selby V; Festenstein R; Mercuri E; Voit T; Faisal AA
    Nat Med; 2023 Jan; 29(1):95-103. PubMed ID: 36658421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD).
    Crabtree NJ; Roper H; Shaw NJ
    Bone; 2022 Jan; 154():116248. PubMed ID: 34718220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative NMRI and NMRS identify augmented disease progression after loss of ambulation in forearms of boys with Duchenne muscular dystrophy.
    Wary C; Azzabou N; Giraudeau C; Le Louër J; Montus M; Voit T; Servais L; Carlier P
    NMR Biomed; 2015 Sep; 28(9):1150-62. PubMed ID: 26215733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy of Duchenne Muscular Dystrophy.
    Hoffman EP
    Handb Exp Pharmacol; 2020; 261():25-37. PubMed ID: 31375923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
    Abreu NJ; Waldrop MA
    Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials.
    Ricotti V; Evans MR; Sinclair CD; Butler JW; Ridout DA; Hogrel JY; Emira A; Morrow JM; Reilly MM; Hanna MG; Janiczek RL; Matthews PM; Yousry TA; Muntoni F; Thornton JS
    PLoS One; 2016; 11(9):e0162542. PubMed ID: 27649492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of growth in ambulatory males with Duchenne muscular dystrophy.
    West NA; Yang ML; Weitzenkamp DA; Andrews J; Meaney FJ; Oleszek J; Miller LA; Matthews D; DiGuiseppi C
    J Pediatr; 2013 Dec; 163(6):1759-1763.e1. PubMed ID: 24103921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients.
    Beenakker EA; Maurits NM; Fock JM; Brouwer OF; van der Hoeven JH
    Eur J Paediatr Neurol; 2005; 9(6):387-93. PubMed ID: 16102988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of emerging molecular and genetic therapies on cardiopulmonary disease in Duchenne muscular dystrophy.
    McKim DA; Cripe TP; Cripe LH
    Pediatr Pulmonol; 2021 Apr; 56(4):729-737. PubMed ID: 33142052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal Study of Three microRNAs in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
    Trifunov S; Natera-de Benito D; Exposito Escudero JM; Ortez C; Medina J; Cuadras D; Badosa C; Carrera L; Nascimento A; Jimenez-Mallebrera C
    Front Neurol; 2020; 11():304. PubMed ID: 32373058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States.
    Thayer S; Bell C; McDonald CM
    J Manag Care Spec Pharm; 2017 Jun; 23(6):633-641. PubMed ID: 28530521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.